Live data · NADAC + Part D CY24 · reviewed daily

Tobramycin and Dexamethasone (TobraDex)

First FDA approval1988-10-15
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$4.01/unit
12 NDCs benchmarked, lowest of all strengths.
Average NADAC
$18.44
Across all dosage forms in distribution.
Highest NADAC
$89.71
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Tobramycin and Dexamethasone used for?

Tobramycin and Dexamethasone is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Tobramycin and Dexamethasone?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Tobramycin and Dexamethasone?

Across 329 Part D plans, Tobramycin and Dexamethasone averages $18.44/unit (NADAC). Lowest available: $4.01/unit. Highest in distribution: $89.71/unit.

Is Tobramycin and Dexamethasone on the FDA shortage list?

No. Tobramycin and Dexamethasone is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.